“DOSE OF REALITY” Big Pharma’s True Track Record Is A Hard Pill To Swallow: Part VI

02-22-2019 Blog Posts

In advance of the U.S. Senate Committee on Finance hearing on February 26, 2019, the Campaign for Sustainable Rx Pricing (CSRxP) is releasing a blog series on what lawmakers can expect to hear from the seven pharma executives who will attend — and why their rhetoric rings hollow when measured against their companies’ track record. […]

“DOSE OF REALITY” Big Pharma’s True Track Record Is A Hard Pill To Swallow: Part V

02-21-2019 Blog Posts

In advance of the U.S. Senate Committee on Finance hearing on February 26, 2019, the Campaign for Sustainable Rx Pricing (CSRxP) is releasing a blog series on what lawmakers can expect to hear from the seven pharma executives who will attend — and why their rhetoric rings hollow when measured against their companies’ track record. […]

“DOSE OF REALITY” Big Pharma’s True Track Record Is A Hard Pill To Swallow: Part IV

02-20-2019 Blog Posts

In advance of the U.S. Senate Committee on Finance hearing on February 26, 2019, the Campaign for Sustainable Rx Pricing (CSRxP) is releasing a blog series on what lawmakers can expect to hear from the seven pharma executives who will attend — and why their rhetoric rings hollow when measured against their companies’ track record. […]

“DOSE OF REALITY” Big Pharma’s True Track Record Is A Hard Pill To Swallow: Part III

02-19-2019 Blog Posts

In advance of the U.S. Senate Committee on Finance hearing on February 26, 2019, the Campaign for Sustainable Rx Pricing (CSRxP) is releasing a blog series on what lawmakers can expect to hear from the seven pharma executives who will attend — and why their rhetoric rings hollow when measured against their companies’ track record. […]

DOSE OF REALITY: Big Pharma’s True Track Record Is A Hard Pill To Swallow – Part II

02-18-2019 Blog Posts

In advance of the U.S. Senate Committee on Finance hearing on February 26, 2019, the Campaign for Sustainable Rx Pricing (CSRxP) is releasing a blog series on what lawmakers can expect to hear from the seven pharma executives who will attend – and why their rhetoric rings hollow when measured against their companies’ track record. […]

DOSE OF REALITY: Big Pharma’s True Track Record Is A Hard Pill To Swallow – Part I

02-15-2019 Blog Posts

As bipartisan momentum to hold Big Pharma accountable and take action on out-of-control drug prices continues to build, the U.S. Senate Committee on Finance is scheduled to question the executives of seven major pharmaceutical manufacturers on February 26, 2019. In advance of the hearing, the second held by the committee on drug pricing this year, […]

What they’re Saying: Reactions to Congress’ Drug Pricing Hearings

02-2-2019 Blog Posts

On Tuesday, the U.S. House Oversight and Reform and Senate Finance Committees held their first hearings on drug pricing. The fact that the first hearings held in these committees were about skyrocketing drug prices sent a clear message to Big Pharma that Congress is ready to hold them accountable for their price-gouging tactics. Check out […]

THEY SAID IT! Drug Companies Have Been Warned

01-31-2019 Blog Posts

Drug Companies Have Been Warned: House & Senate Chairmen & Ranking Members Pledge To Work Together To Hold Big Pharma Accountable U.S. Senate Chairman Of The Committee On Finance Chuck Grassley: “You will hear many numbers describing the costs of prescription drugs.  Those numbers are impressive, but the stories I have heard from patients, doctors, […]

Second Opinion: R&D Is Not To Blame For Skyrocketing Drug Costs

01-17-2019 Blog Posts

The jig is up – a new report showsthat “the skyrocketing cost of many prescription drugs in the U.S. can be blamed primarily on price increases, not expensive new therapies or improvements in existing medications as drug companies frequently claim.” The new research, published in Health Affairs, shows that drugs are increasing at a rate faster than […]

Second Opinion: No, Big Pharma Is Not Changing

01-11-2019 Blog Posts

Right on cue, dozens of pharmaceutical companies rang in the new year by increasing hundreds of drug prices by up to 15 times the rate of inflation – despite the fact that their profits continue to far exceed spending on research and development.  In just one week: Allergan increased the price of two dozen drugs […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.